Uppsala 6th November 2017


New animal study shows additional benefits with PharmaShell®


In Nanexa’s ongoing animal study, the first results have shown that the further development of the PharmaShell® technology significantly reduces the initial concentration peak.

 Nanexa’s previous animal study showed that the plasma concentrations of the drug in the test animals after an initial higher concentration peak could be maintained at constant levels over the three weeks of the study. The initial peak may be beneficial in some disease treatments, while in other cases it is desirable to minimize it to directly reach an even drug concentration in the blood.

To meet this need, Nanexa has further developed PharmaShell® and the first animal study results with the optimized PharmaShell® shell show that the initial concentration peak was lowered by as much as 85%.


The company’s CEO David Westberg comments

“These results are important to us. It shows that we can control the plasma profile of drugs in the blood in a controlled manner by varying certain characteristics of PharmaShell®. In this way we can meet the needs of pharmaceutical companies to optimize the treatment effect in their product development projects.

The pharmaceutical companies have specifically requested drug delivery systems that can minimize the initial concentration peak after administration and with our new study results, I hope that the interest in PharmaShell® will be further increased. I also look forward with confidence to more results from the same animal study and further animal studies are also planned in the near future. ”


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se



About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.